Clinical and Experimental Hypertension is converting to Open Access
The journal publishes high quality original research articles and review articles in the general area of hypertension, including those studying the mechanisms and treatment of hypertension.
It plans to foster the immediate and wide-scale dissemination of research results through adoption of an Open Access (OA) model. Every submission will continue to be subject to the usual vigorous reviewing process by experts in the field, and to help with this process, the journal has a strong editorial board of prominent and respected academics.
As part of this transition, from 28th June all manuscripts submitted to the journal will, if accepted, be required to pay an article publishing charge (APC) which can be covered by an author’s funder or institution. We look forward to receiving your submissions and welcome your support in this exciting new open access chapter for the journal.
Clinical and Experimental Hypertension is particularly interested in receiving manuscripts on:
Antihypertensive agents
Circulatory control
Drug development and application
Etiology
Mechanisms of action
Neurogenic mechanisms
Pathophysiology
Pharmacological and nonpharmacological treatment
All aspects of human and animal hypertension
The journal publishes full articles as well as solicited and unsolicited reviews and commentaries that extend current understanding as well as facilitate the timely and successful detection, management, control, and prevention of hypertension-related conditions..
Editor-In-Chief
Professor Mustafa F. Lokhandwala joined the University of Houston College of Pharmacy as a graduate student and has since been elevated to numerous leadership posts within the college, including Department Chair (1980-1991), Dean (1992-2002), Executive Vice-Dean for Research (2003-2019), and Director of the Heart and Kidney Institute (2006-2021). He secured approval from the Texas Higher Education Coordinating Board for establishing Ph.D. and Pharm.D. programs at the college in the 1990s, increasing funding research to over $11 million in FY2018. He is also Fellow of American Heart Association and the American Society of Nephrology.
His research program focuses on understanding the mechanisms of cardiovascular diseases such as hypertension, and receives continuous support from the National Institutes of Health (NIH). His research has produced more than 200 peer-reviewed journal articles and reviews, 200-plus abstracts, and more than two dozen books and book chapters.
Why publish open access?
Increase the visibility and readership of your research by publishing in a fully open access journal.
Make an impact beyond the academy by making your article accessible to anyone, anywhere (including readers in industry and even policy-makers).
Freely share your work with no restrictions or paywall.
Retain ownership of your research through our unrestrictive publishing agreements.
Discounts and waivers for researchers in developing countries are available. The journal will also consider requests for discretionary APC waivers. Find out if your institution or country has an open access agreement to publish with us.